http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yaerim Kim,Eunjeong Kang,Dong-Wan Chae,Jung Pyo Lee,Sik Lee,Soo Wan Kim,Jang-Hee Cho,Miyeun Han,Seungyeup Han,Yong Chul Kim,Dong Ki Kim,Kwon Wook Joo,Yon Su Kim,Hajeong Lee 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.5
Background/Aims: Renal recovery of a kidney donor after undergoing nephrectomy though challenging is essential. We aimed to examine the effect of estimated glomerular filtration rate (eGFR) percent change at 1-month post-donation on insufficient kidney function after kidney donation. Methods: A total of 3,952 living kidney donors who underwent donor nephrectomy from 1982 to 2019 from eight different tertiary hospitals in Korea were initially screened. Percent changes in the eGFR from baseline to 1-month post-donation were calculated. The degree of percent changes was categorized by quartile, and the 1st quartile was regarded as the group with the lowest decreased eGFR at 1-month after donation. The remaining eGFR less than 60 mL/min/1.73 m2 was the endpoint. The Cox proportional hazard model was used for evaluating the impact of initial eGFR and eGFR percent change at 1-month post-donation on the condition with remaining eGFR < 60 mL/min/1.73 m2. In the multivariate analysis, we used variables with a p < 0.1 in the univariate analysis. Results: A total of 1,585 donors were included in the analysis. During 62.2 ± 49.3 months, 13.7% of donors showed renal insufficiency. The 4th (adjusted hazard ratio [aHR], 10.41; 95% confidence interval [CI], 5.15 to 21.04) and the 3rd (aHR, 4.29; 95% CI, 2.15 to 8.56) quartiles of percent change in eGFR and the pre-donation eGFR (aHR, 0.90; 95% CI, 0.88 to 0.92) were associated with the development of renal insufficiency. Conclusions: The impact of worse initial renal recovery on renal insufficiency was pronounced in donors with lower pre-donation eGFRs. Additionally, worse initial renal recovery of remaining kidney affected the long-term development of renal insufficiency in kidney donors.
Expected Future Market Volume of HTS Equipment in South Korea
Jae-young Yoon,Seung-ryul Lee,B. Yang,SeungYeup Lee,Youngjin Won 한국자기학회 2011 Journal of Magnetics Vol.16 No.2
This paper shows the entire future market volume of the HTS power industry, one of main smart grid equipment, in the case of the final market penetration ratio reaching 100% in the domestic market (South Korea). In this paper, the market penetration ratio is determined using the judgment method, with the market penetration S-curve induced using the Delphi method and the Product Life Cycle from 2011 (supposed launching year, not realistic physical year), to 2050 (expected final target year). This paper analyzes the HTS market penetration ratio of each stage, apparent innovation, early adapters, and the early/late majority and laggard stage, using the S-curve, thus calculating the total future market volume of HTS equipment in the positive sense. Finally, this paper estimates the quantitative analysis results for the HTS4-items (cable, FCL, transformer, rotation machine) of each year within the domestic market.
Kim Yaerim,Park Hayne Cho,Ryu Hyunjin,Kim Yong Chul,Ahn Curie,Lee Kyu-Beck,Kim Yeong Hoon,Han Seungyeup,Bae Eun Hui,Jeong Kyungjo,Choi Jungmin,Oh Kook-Hwan,Oh Yun Kyu 대한의학회 2023 Journal of Korean medical science Vol.38 No.38
Background: Factors related to the development and severity of polycystic liver disease (PLD) have not been well established. We aimed to evaluate the genetic and epidemiologic risk factors of PLD in patients with autosomal dominant polycystic kidney disease (ADPKD). Methods: Adult patients with inherited cystic kidney disease were enrolled from May 2019 to May 2021. Demographic, clinical, and laboratory data were collected at the initial study visit. The severity of PLD was graded based on the height-adjusted total liver volume: < 1,000 mL/m (Gr1), 1,000–1,800 mL/m (Gr2), and > 1,800 mL/m (Gr3). Targeted exome sequencing was done by a gene panel including 89 ciliopathy-related genes. We searched out the relative factors to the presence and the severity of PLD using logistic regression analysis. Results: Of 602 patients with typical ADPKD, 461 (76.6%) patients had PLD. The patients with PLD showed female predominance and a higher frequency of other ADPKD-related complications. The genetic variants with truncating mutation of PKD1 (PKD1-proteintruncating [PT]) or PKD2 commonly affected the development and severity of PLD. An older age, female sex, and higher kidney volume with Mayo classification 1C-1E was significantly associated with the development of PLD, but not with the severity of PLD. On the other hand, higher body mass index, lower hemoglobin, and higher alkaline phosphatase (ALP) were the significant risk factors of severe PLD (≥ Gr2). Conclusion: Hepatic involvement in ADPKD could be related to kidney manifestations and genetic variants including PKD1-PT or PKD2. Monitoring hemoglobin and ALP and evaluating the genetic variants might help predict severe PLD.
( Hyuk Huh ),( Yong Soo Kim ),( Wookyung Chung ),( Yong Lim Kim ),( Yaerim Kim ),( Seungyeup Han ),( Yeonsoon Jung ),( Ki Young Na ),( Kyu Beck Lee ),( Yun Kyu Oh ),( Hyeong Cheon Park ),( Seung Hyeok 대한신장학회 2023 Kidney Research and Clinical Practice Vol.42 No.2
Background: Tolvaptan reduces height-adjusted total kidney volume (htTKV) and renal function decline in autosomal dominant polycystic kidney disease (ADPKD). This study was aimed at investigating the efficacy and safety of tolvaptan in Korean patients with ADPKD during the titration period. Methods: This study is a multicenter, single-arm, open-label phase 4 study. We enrolled 108 patients with ADPKD (age, 19-50 years) with an estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73 ㎡ and factors defined as indicative of rapid disease progression. After tolvaptan titration, we evaluated efficacy and side effects and assessed factors associated with the effects. Results: After titration for 4 weeks, eGFR and htTKV decreased by 6.4 ± 7.9 mL/min/1.73 ㎡ and 16 ± 45 mL/m, respectively. No serious adverse drug reactions were observed during the titration period. The greatest eGFR decline was observed in the first week, with a starting tolvaptan dose of 45 mg. Multivariate linear regression for htTKV decline showed that the greater the change in urine osmolality (Uosm), the greater the decrease in htTKV (β, 0.436; p = 0.009) in the 1D group stratified by the Mayo Clinic image classification. Higher baseline eGFR was related to a higher htTKV reduction rate in the 1E group (β, -0.642; p = 0.009). Conclusion: We observed short-term effects and safety during the tolvaptan titration period. The decline of htTKV can be predicted as a short-term effect of tolvaptan by observing Uosm changes from baseline to end of titration in 1D and baseline eGFR in 1E groups.